Home Science & Medicine Targeted Therapy

Targeted Therapy

Feature articles about advances and current developments in targeted therapy that have significant impact or impact potential on thoracic oncology.

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...

By Julien Mazieres, MD, PhD The standard of care for patients postresection for lung cancer is adjuvant chemotherapy, usually a platinum-based regimen.1 The deciphering of...

Updated Results from the Phase III ALEX Trial: Embracing Hazard Ratios

By D. Ross Camidge, MD, and Mary W. Redman, PhD Updates of the primary analysis of the phase III ALEX trial were presented at the...

ALK Testing in Europe

By Enriqueta Felip, MD, PhD ALK-directed TKIs are effective first- and second-line therapies in patients with ALK rearrangements. Testing of all patients with stage IV...

Adjuvant Gefitinib Extended Disease-Free Survival in Patients With Stage II/IIIA Non-Small Cell Lung Cancer...

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: IASLC Lung Cancer News is pleased to provide the following overview, which is followed by expert commentary...

Osimertinib: A New Option in Non-Small Cell Lung Cancer – Q&A with David R....

By Erik J. MacLaren, PhD Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use...

Alectinib and ALK-Positive Non-Small Cell Lung Cancer – Q&A with Alice T. Shaw, MD,...

By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line...

Benefit of EGFR Mutation Analysis from Plasma Cell-Free DNA for Treatment of Advanced Non-Small...

By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can...

Meeting News